258 related articles for article (PubMed ID: 28674297)
1. [Characterization of Therapeutic Monoclonal Antibodies by Using FcγR-expressing Reporter Cell Lines].
Tada M; Ishii-Watabe A
Yakugaku Zasshi; 2017; 137(7):837-843. PubMed ID: 28674297
[TBL] [Abstract][Full Text] [Related]
2. Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies.
Tada M; Ishii-Watabe A; Suzuki T; Kawasaki N
PLoS One; 2014; 9(4):e95787. PubMed ID: 24752341
[TBL] [Abstract][Full Text] [Related]
3. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
[TBL] [Abstract][Full Text] [Related]
4. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
5. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
6. Development of cell-based assay for predictively evaluating the FcγR-mediated human immune cell activation by therapeutic monoclonal antibodies.
Takakura M; Tada M; Ishii-Watabe A
Biochem Biophys Res Commun; 2017 Mar; 485(1):189-194. PubMed ID: 28196745
[TBL] [Abstract][Full Text] [Related]
7. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
Treffers LW; van Houdt M; Bruggeman CW; Heineke MH; Zhao XW; van der Heijden J; Nagelkerke SQ; Verkuijlen PJJH; Geissler J; Lissenberg-Thunnissen S; Valerius T; Peipp M; Franke K; van Bruggen R; Kuijpers TW; van Egmond M; Vidarsson G; Matlung HL; van den Berg TK
Front Immunol; 2018; 9():3124. PubMed ID: 30761158
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
9. Surrogate CD16-expressing effector cell lines for determining the bioactivity of therapeutic monoclonal antibodies.
Gurjar SA; Derrick JP; Dearman RJ; Thorpe R; Hufton S; Kimber I; Wadhwa M
J Pharm Biomed Anal; 2017 Sep; 143():188-198. PubMed ID: 28605680
[TBL] [Abstract][Full Text] [Related]
10. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
11. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
12. Fcγ Receptor Activation by Human Monoclonal Antibody Aggregates.
Tada M; Aoyama M; Ishii-Watabe A
J Pharm Sci; 2020 Jan; 109(1):576-583. PubMed ID: 31676270
[TBL] [Abstract][Full Text] [Related]
13. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells.
Chung S; Lin YL; Reed C; Ng C; Cheng ZJ; Malavasi F; Yang J; Quarmby V; Song A
J Immunol Methods; 2014 May; 407():63-75. PubMed ID: 24704820
[TBL] [Abstract][Full Text] [Related]
14. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
16. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.
Bruggeman CW; Dekkers G; Bentlage AEH; Treffers LW; Nagelkerke SQ; Lissenberg-Thunnissen S; Koeleman CAM; Wuhrer M; van den Berg TK; Rispens T; Vidarsson G; Kuijpers TW
J Immunol; 2017 Jul; 199(1):204-211. PubMed ID: 28566370
[TBL] [Abstract][Full Text] [Related]
18. [Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review].
Qu YH; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1370-5. PubMed ID: 21129296
[TBL] [Abstract][Full Text] [Related]
19. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells.
Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM
Front Immunol; 2021; 12():641521. PubMed ID: 33796107
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]